Kip1
Myeloid leukemia factor 1 (MLF1) was originally identified in a (3;5) translocation with nucleophosmin (NPM) associated with acute myeloid leukemia (AML) (Yoneda-Kato et al., 1996) and expressed in a disproportionately high number of M6 erythroleukemias (Raimondi et al., 1989) . Interestingly, elevated wild-type MLF1 is associated with malignant progression and poor prognosis in non-t(3;5) AML (Matsumoto et al., 2000) . MLF1 resides primarily in the cytoplasm, with some punctate nuclear localization, whereas NPM-MLF1 is almost exclusively nuclear (Lim et al., 2002; Williams et al., 1999; Yoneda-Kato et al., 1996) . Little is known about the domains or function of MLF1 apart from a 14-3-3 binding motif, and an association with a novel adaptor molecule Madm (Hitzler et al., 1999; Williams et al., 1999; Lim et al., 2002) .
The murine homologue, Mlf1 (Hitzler et al., 1999) , was identified independently by this laboratory as Hls7, a gene expressed when erythroleukemic cells underwent a spontaneous lineage switch and displayed the phenotypic features of monoblastoid cells (Williams et al., 1999) . Significantly, ectopic expression of Mlf1 reprogrammed erythroleukemic cells to display a blast-like phenotype (Williams et al., 1999) . Although Mlf1 induced a dramatic phenotypic change, it did not reduce the levels of erythroid transcription factors GATA-1, EKLF and NF-E2; furthermore, Mlf1 did not restrict Epo-initiated signalling as the Epo receptor, STAT5 and MAP Kinase were all phosphorylated normally. Importantly, Mlf1 was able to influence lineage commitment of primary hemopoietic progenitors by restricting erythroid colony formation and enhancing the emergence of myeloid colonies (Williams et al., 1999) .
The expansion of erythroid progenitors, prior to terminal differentiation, is associated with upregulation of cyclin-E and cyclin-dependent kinases (cdk) (Dai et al., 2000) . Conversely, exit from the cell cycle, essential for erythroid maturation is mediated by inhibitors which restrict the activity of specific cdks (Matushansky et al., 2000a,b) . Epo-induced differentiation, and associated cell cycle arrest, involves accumulation of p27 Kip1 and suppression of cdk2 kinase activity (Hsieh et al., 2000) . Several different models examining erythroid maturation have consistently shown an increase in p27
Kip1 (Panzenbock et al., 1998; Hsieh et al., 2000; Matushansky et al., 2000a,b; Tamir et al., 2000; Jacobs-Helber et al., 2002; Bouscary et al., 2003) . Interestingly, p27
Kip1À/À mice display an erythroid hyperplasia (Fero et al., 1996) , and it has been suggested that p27
Kip1 levels are downregulated by the NPM-MLF1 fusion protein (Yoneda-Kato and Kato, 1999) . In this study, we examined the impact of ectopic Mlf1 expression on p27 Kip1 levels and cell cycle arrest associated with erythroid terminal differentiation.
We utilized the J2E murine erythroleukemic cell line that is immortalized at the proerythroblast stage of erythroid maturation (Klinken et al., 1988) . This block in differentiation is released upon exposure to Epo -after a burst of proliferation, the differentiating cells exit the cell cycle, synthesize hemoglobin and undergo morphological changes producing polychromatic and orthochromatic erythroblasts, as well as a proportion of reticulocytes (Busfield and Klinken, 1992; Tilbrook et al., 1997) . Interestingly, Epo-induced differentiation of J2E cells is potentiated by Olomucine which inhibits cyclin-E/cdk2 activity and slows the rate of cell growth (unpublished observations).
Unlike control J2E cells, clones ectopically expressing Mlf1 (J-Mlf1) did not synthesize hemoglobin in response to Epo (Figure 1a ). The larger, blast-like J-Mlf1 cells also displayed none of the morphological features associated with erythroid maturation following Epo stimulation (Figure 1b ), nor did they undergo Epoinitiated cell cycle exit demonstrated by accumulation of cells in G 0 /G 1 (Figure 1c ). Thus, Mlf1 prevents hemoglobin synthesis, morphological maturation and growth arrest during erythroid terminal differentiation, despite activation of Epo signalling pathways and the presence of erythroid transcription factors (Williams et al., 1999) .
Since J-Mlf1 cells did not exit the cell cycle upon exposure to Epo, the levels of the cell cycle inhibitor p27 Kip1 were examined in J2E and J-Mlf1 cells (Figure 2a ). The Epo-induced rise of p27
Kip1 in J2E cells is comparable with previous observations (Hsieh et al., 2000) . In contrast, there was no increase in p27
Kip1 in JMlf1 cells following Epo treatment, indicating that Mlf1 is able to prevent the accumulation of this inhibitor.
Cyclin-E/cdk2 activity is required for G 1 /S transition in normal cells (Ohtsubo et al., 1995) and binding of p27
Kip1 to this complex inhibits its activity. It is noteworthy, therefore, that binding of p27
Kip1 to the cyclin-E/cdk2 complex was reduced substantially in JMlf1 cells compared with parental J2E cells (Figure 2b) . Moreover, the decrease in cdk2 activity observed in J2E cells, did not occur in J-Mlf1 cells (Figure 2c ). Thus, four pieces of evidence suggest Mlf1 suppresses differentiation by interfering with Epo-induced cell cycle regulation: (i) cell cycle arrest was prevented, (ii) p27
Figure 1 Mlf1 inhibits Epo-induced maturation and cell cycle exit. J2E cells (Klinken et al., 1988) , infected with the MSCV retroviral vector alone and J-Mlf1 cells (originally described as J-Hls7 cells) (Williams et al., 1999) were cultured in the presence or absence of 5 U/ml Epo for 48 h. Two unique J-Mlf1 clones (J-Mlf1.1 and J-Mlf1.7) obtained via independent retroviral integration were used throughout this study (Williams et al., 1999) . Kip1 (PharMingen, CA, USA) and loading control, p42 MAP Kinase (Santa Cruz Biotechnology, CA, USA). (b) Cyclin E was immunoprecipitated (IP) from wholecell lysates using anti-cyclin-E antibodies (Santa Cruz Biotechnology, CA, USA), before the complexes were separated by SDS-PAGE and the presence of cdk2 and p27
Kip1 demonstrated by immunoblotting. (c) Cdk2 activity was determined by histone phosphorylation using [g 32 P]ATP as previously described (Tilbrook et al., 1997) . Activity was quantitated using Imagequant; the activity of uninduced J2E cells was designated as 100% and all other values are shown relative to this control. Each experiment is a representative of at least three independent experiments Mlf1 inhibits erythroid cell cycle exit LN Winteringham et al levels failed to rise, (iii) p27
/cyclin-E complexes were reduced and (iv) cdk2 activity was not inhibited.
The regulation of p27 Kip1 was then examined in J2E and J-Mlf1 cells. No change in p27 Kip1 RNA was detected following Epo stimulation ( Figure 3a) . As p27 Kip1 protein levels are also controlled by protein degradation , the proteasomal inhibitor MG132 was added to J-Mlf1 cultures induced with Epo. The fivefold increase in p27
Kip1 protein following treatment with MG132 indicates that proteasomes were actively involved in degrading the inhibitor (Figure 3b) . Significantly, Cul1 and Skp2, components of the ubiquitin E3 ligase SCF Skp2 , associated with p27
Kip1 degradation, decreased in Epo-treated J2E cells, whereas expression was maintained or raised in J-Mlf1 cells (Figure 3c ). Taken together these data indicate that Mlf1 may regulate an Epo-mediated pathway involved in p27
Kip1 turnover. Recently, we have demonstrated that the thyroid hormone T 3 is a potent antagonist of erythroid differentiation -removal of T 3 results in marked increases in p27 Kip1 , rapid cessation of replication and almost complete differentiation of J2E cells (Ingley et al., 2001) . Since J-Mlf1 cells were restricted in their ability to mature in response to Epo, we examined the effect of T 3 withdrawal on the differentiation capacity of these cells. Strikingly, virtually all J-Mlf1 cells synthesized hemoglobin upon withdrawal of T 3 (Figure 4a ). Moreover, these cells underwent morphological changes characteristic of erythroid terminal differentiation (Figure 4b ), demonstrating that J-Mlf1 cells still retained the ability to mature along the erythroid pathway. Importantly, Mlf1 did not prevent the increase in p27
Kip1 after removal of T 3 (Figure 4c ). These observations suggest that the inhibitory effects of Mlf1 on p27
Kip1 were restricted to a pathway activated by Epo.
In contrast with erythroid cells, ectopic expression of Mlf1 potentiates myeloid maturation -this is manifest by increased myeloid colony formation and elevated levels of Cd11b on M1 monoblastoid cells (Williams et al., 1999; Lim et al., 2002) . As p27
Kip1 levels increase during myeloid maturation (Dimberg et al., 2002) , the effects of Mlf1 on p27
Kip1 were examined in M1 cells. Figure 5a shows that p27
Kip1 rose in M1 cells, as well as those expressing exogenous Mlf1 (M-Mlf1). This increase in p27
Kip1 was compatible with the ability of M-Mlf1 cells to cease dividing and mature into macrophages (Figure 5b) . Thus, Mlf1 facilitates myeloid differentiation (Williams et al., 1999; Lim et al., 2002) and does not impede LIF-induced elevation of p27 Kip1 . The results presented in this manuscript provide evidence that Mlf1 prevents Epo-initiated terminal differentiation and cell cycle exit by suppressing a rise in p27 Kip1 (Figure 2 ). The maintenance of Cul1 and Skp2 in J-Mlf1 cells correlates well with persistent proteasomal degradation of p27
Kip1 (Figures 3b and c) . Significantly, an inverse relationship between Skp2 and p27
Kip1 during Epo-mediated proliferation has been demonstrated recently (Bouscary et al., 2003) . Furthermore, the Epo-induced decline in Cul1 shown here in J2E cells is consistent with the established decrease in cmyc (Busfield and Klinken, 1992) , which has been shown to directly regulate transcription of the Cul1 gene (O'Hagan et al., 2000) .
Since Mlf1 is present in nuclear spots and can reprogram erythroleukemic cells (Williams et al., 1999) it may act as a transcriptional regulator. Interestingly, Drosophila Mlf associates with the transcription factor DREF (Ohno et al., 2000) , which regulates proliferation-related genes (Hochheimer et al., 2002) . Similar to Mlf1, the DNA-binding protein MLL, is involved in a translocation producing AML, and also promotes myeloid maturation with cell cycle arrest at the expense of the erythroid pathway (Caslini et al., 2000) . Furthermore, the transcription factor GATA-1 can, like Mlf1, reprogram hemopoietic cells (Kulessa et al., 1995; Yamaguchi et al., 1998) and is capable of cell cycle regulation ( Whyatt et al., 1997; Tanaka et al., 2000; Rylski et al., 2003) .
The preferential inhibition of Epo-induced accumulation of p27
Kip1 by Mlf1 described here, may explain why t(3;5) produces a disproportionately high number of erythroleukemias (Raimondi et al., 1989) . The fusion protein NPM-MLF1 may be leukemogenic by downregulating p27
Kip1 (Yoneda-Kato and Kato, 1999) , thus preventing erythroid cell cycle withdrawal and creating a 'block in differentiation'. While the precise biochemical function of Mlf1 awaits elucidation, these data show that Mlf1 interferes with the Epo-responsive pathway involved in growth arrest and maturation.
